Budesonide + formoterol fumarate dihydrate for the treatment of asthma

References

• Global strategy for asthma management and prevention [revised May 2014): Global Initiative for Asthma [GINA). [cited 2016 January 8] Available from: www.ginasthma.com.
   Google Scholar
• Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J. 2002;19:182–191.
   PubMed Web of Science ®Google Scholar
• Marceau C, Lemière C, Berbiche D, et al. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol. 2006; 118:574–58.
   PubMed Web of Science ®Google Scholar
• Edwards SJ, Von Maltzahn R, Naya IP, et al. Budesonide/formoterol for maintenance and reliever therapy of asthma: A meta analysis of randomised controlled trials. Int J Clin Pract. 2010;64:619–627.
   PubMed Web of Science ®Google Scholar
• Peters M. Single-inhaler combination therapy for maintenance and relief of asthma: A new strategy in disease management. Drugs. 2009;69:137–150.
   PubMed Web of Science ®Google Scholar
• Ankerst J. Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma. J Asthma. 2005;42:715–724.
   PubMed Web of Science ®Google Scholar
• Wolthers OD. Pharmacokinetics and systemic activity of a new patent of an inhaled corticosteroid/long-acting beta2-agonist combination for use in asthma therapy. Recent Pat Inflamm Allergy Drug Discov. E pub ahead of print. PMID: 26581314. 2015.
   PubMedGoogle Scholar
• Tamm M, Richards DH, Beghé B, et al. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice. Respir Med. 2012;106(suppl 1):S9–S19. doi:10.1016/S0954-6111[12970005-7.
   Web of Science ®Google Scholar
• Beasley RW, Donohue JF, Mehta R, et al. Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double blind randomised controlled trial. BMJ Open. 2015;5:e006131. doi:10.1136/bmjopen-2014-006131.
   PubMed Web of Science ®Google Scholar
• Dissanayake S, Jain M, Grothe B, et al. An evaluation of comparative treatment effects with high and low dose fluticasone propionate/formoterol combination in asthma. Pulm Pharmacol Ther. 2015;35:19–27. doi:10.1016/j.pupt.2015.10.001. Epub 2015 Nov 10.
   PubMed Web of Science ®Google Scholar
• Fukuchi Y, Samoro R, Fassakhov R, et al. Budesonide/fomoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results. Respiropogy. 2013;18(5):866–873.
   PubMed Web of Science ®Google Scholar
• Malmberg LP, Everard ML, Haikarainen J, et al. Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler®. J Aerosol Med Pulm Drug Deliv. 2014;27(5):329–340.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Arp J, Keeqstra JR, et al. Spiromax, a new dry powder inhaler: dose consistency under simulated real-world conditions. J Aerosol Med Pulm Drug Deliv. 2015;28(5):309–319.
   PubMed Web of Science ®Google Scholar
• Heyder J, Gebhart J, Rudolf G, et al. Deposition of particles in the human respiratory tract in the size range 0.005-15µm. J Aerosol Sci. 1986;17:811–825.
   Web of Science ®Google Scholar
• Chrystyn H, Safioti G, Keegstra JR, et al. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: an in-vitro comparison of Spiromax with Turbuhaler. Int J Pharmacut. 2015;491:268–276.
   PubMed Web of Science ®Google Scholar
• Wolthers OD. Extra-fine inhaled corticosteroids, pharmacokinetics and systemic activity in children with asthma. Pediatr Allergy Immunol. 2015; [Epub ahead of print]. PMID:26360937. doi:10.1111/pai.12491.
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT. Pharmacological aspects of glucocorticoid therapy. In: Wolthers OD, editor. Exogenous glucocorticoids in paediatric asthma. Kerala: Transworld Research Network. 2007. p. 1–18.
   Google Scholar
• Bartow RA, Brogden RN. Formoterol. an update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs. 1998;55:303–322.
   PubMed Web of Science ®Google Scholar
• Derendorf H, Hochhaus G, Meibohm BJ, et al Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol. 1998;101(4):S440–446.
   Google Scholar
• Miller-Larsson A, Jansson P, Runström A, et al. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med. 2000;162(4):1455–1461.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504.
   PubMed Web of Science ®Google Scholar
• Lähelmä S, Sairanen U, Haikarainen J, et al. Equivalent lung dose and systemic exposure of budesonide/formoterol combination via Easyhaler and Turbuhaler. J Aerosol Med Pulm Drug Deliv. 2015;28(6):462–473.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and corticosteroids establishing therarpy (FACET) international study group. N Engl Med. 1997;337(20):1405–1411.
   PubMed Web of Science ®Google Scholar
• O`Byrne PM, Naya IP, Kallen A, et al. Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. Chest. 2008;134(6):1192–1199.
   PubMed Web of Science ®Google Scholar
• O`Byrne PM. Therapeutic strategies to reduce asthma exacerbations. J Allergy Clin Immunol. 2011;128(29):257–263.
   PubMed Web of Science ®Google Scholar
• Lee BJ, Jeung YJ, Lee JY, et al. Potential masking of airway eosinophilic inflammation by combination therapy in asthma. Allergy Astma Immunol Res. 2014;6(2):175–178.
   PubMed Web of Science ®Google Scholar
• Kips JC, O`Connor BJ, Inman MD, et al. A long-term study of the anti-inflammatory effect of low-dose budesonide plus formotrol versus high-dose budesonide in asthma. Am J Crit Care Med. 2000;16(3Pt1):996–1001.
   Google Scholar
• Green RH, Brightling CE, McKenna S, et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. Eur Repir J. 2006;27(6):1144–1151.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Pizzichini E, Ställberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest. 2006;129(2):246–256.
   PubMed Web of Science ®Google Scholar
• Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin. 2004;20(9):1403–1416.
   PubMed Web of Science ®Google Scholar
• O`Byrne PM, Bisgaard H, Godard PP, et al. Budeonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171(2):129–136.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomized controlled, double-blind study. Lancet. 2006;368(9537):744–753.
   PubMed Web of Science ®Google Scholar
• Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. In J Clin Pract. 2007;61(5):725–736.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Boulet LP, Peters MJ, et al. Budesonde/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med. 2007;101(12):2437–2446.
   PubMed Web of Science ®Google Scholar
• Patel M, Pilcher J, Pritchard A, et al. Efficacy and safety of maintenance and reliever combination budesonide-formotrol inhaler in patients with asthma at risk of severe exacerbations: a randomized trial. Lancet Respir Med. 2013;1(1):32–42.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, DÙrzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy; an effective asthma treatment option? Eur Respir J. 2005;26:819–828.
   PubMed Web of Science ®Google Scholar
• Demoly P, Louis R, Søes-Petersen U, et al. Budesonide/formoterol maintenance and reliever therapy verus conventional best practice. Repir Med. 2009;103:1623–1632.
   PubMed Web of Science ®Google Scholar
• Aubier M, Buhl R, Ekström T, et al. Comparison of two twice.daily doses of budesonide/fomoterol maintenance and reliever therapy. Eur Repir J. 2010;36(3):524–530.
   PubMed Web of Science ®Google Scholar
• Ställberg B, Naya I, Ekelund J, et al. Real-life use of budesonide/formoterol in clinical practice: a 12-month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy. In J Clin Pharmacol Ther. 2015;53(6):447–455.
   Web of Science ®Google Scholar
• Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance) for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013;4:CD007313. doi:10.1002/14651858.CD007313.pub3.
   Google Scholar
• Wolthers OD, Honour JW. Hypothalamic-pituitary-adrenal function in children with asthma and rhinitis treated with topical glucocorticosteroids. Clin Exper Allergy. 1998;28:545–550.
   PubMed Web of Science ®Google Scholar
• Wolthers OD, Daley-Yates PT. Hypothalamic-pituitary-adrenal function. In: Wolthers OD, editor. Exogenous glucocorticoids in paediatric asthma. Kerala: Transworld Research Network; 2007. p. 19–33.
   Google Scholar
• Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma related deaths. Ann Intern Med. 2006;144:904–912.
   PubMed Web of Science ®Google Scholar
• Sears MR, Radner F. Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respiratory Med. 2009;103:1960–1968.
   PubMed Web of Science ®Google Scholar
• Sears MR, Radner F. Safety of formoterol in asthma clinical trials: an update. Eur Respir J. 2014;43(1):103–114.
   PubMed Web of Science ®Google Scholar
• Ankerst J, Persson G, Weibull E. Tolerability of high dose of budesonide/formoterol in a single inhaler ni patients with asthma. Pulm Pharmacol Ther. 2003;16(3):147–151.
   PubMed Web of Science ®Google Scholar
• Heuck C, Heickendorff L, Wolthers OD. A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide. Arch Dis Child. 2000;83:334–339.
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Le Roux P, Bjärmer D, et al. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest. 2006;130(6):1733–1743.
   PubMed Web of Science ®Google Scholar
• Eid NS, Noonan MJ, Chipps B, et al. Once- vs twice-daily budesonide/formoterol in 6- to 15-year-old patients with stable asthma. Pediatrics. 2010;126(3):e565–575.
   Google Scholar
• Lundh A, Sismondo S, Lexchin J, et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012;12:MR000033. doi:10.1002/14651858.MR000033.pub2.
   PubMed Web of Science ®Google Scholar
• Kew KM, Karner C, Mindus SM, et al. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013;12:CD009019. doi:10.1002/14651858.CD009019.pub2.
   Google Scholar
• Bateman ED, Harrison TW, Quirce S, et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res. 2011;12:38. doi:10.1186/1465-9921-12-38.
   PubMed Web of Science ®Google Scholar
• Buhl R, Kuna P, Peters MJ, et al. The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy. Respir Res. 2012;13:59. doi:10.1186/1465-9921-13-59.
   PubMed Web of Science ®Google Scholar
• Ställberg B, Ekström T, Neij F, et al. A real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respiratory Med. 2008;102:1360–1370.
   PubMed Web of Science ®Google Scholar
• Scichilone N. Asthma control: the right inhaler for the right patient. Adv Ther. 2015;32:285–292.
   PubMed Web of Science ®Google Scholar
• Syed YY. Fluticasone furoate/vilanterol: areview of its use in patients with asthma. Drugs. 2015;75:407–418.
   PubMed Web of Science ®Google Scholar